Cargando…

Differential effects of lenalidomide during plasma cell differentiation

Thalidomide, lenalidomide and pomalidomide have greatly improved the outcome of patients with multiple myeloma. However, their effects on plasma cells, the healthy counterpart of myeloma cells, are unknown. Here, we investigated lenalidomide effects on normal human plasma cell generation using an in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jourdan, Michel, Cren, Maïlys, Schafer, Peter, Robert, Nicolas, Duperray, Christophe, Vincent, Laure, Ceballos, Patrice, Cartron, Guillaume, Rossi, Jean-François, Moreaux, Jérôme, Chopra, Rajesh, Klein, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053712/ https://www.ncbi.nlm.nih.gov/pubmed/27057635 http://dx.doi.org/10.18632/oncotarget.8581

Ejemplares similares

Characterization of human FCRL4-positive B cells
por: Jourdan, Michel, et al.
Publicado: (2017)

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
por: Kassambara, Alboukadel, et al.
Publicado: (2017)

EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
por: Herviou, Laurie, et al.
Publicado: (2019)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators
por: Kassambara, Alboukadel, et al.
Publicado: (2021)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
por: Mahtouk, Karène, et al.
Publicado: (2010)

DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets
por: Gabellier, Ludovic, et al.
Publicado: (2020)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment
por: Lamure, Sylvain, et al.
Publicado: (2020)

GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2015)

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
por: Szablewski, Vanessa, et al.
Publicado: (2018)

Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis
por: Mausset-Bonnefont, Anne-Laure, et al.
Publicado: (2019)

Gene expression-based risk score in diffuse large B-cell lymphoma
por: Bret, Caroline, et al.
Publicado: (2012)

Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma
por: Bret, Caroline, et al.
Publicado: (2013)

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients
por: Gandhi, Anita K., et al.
Publicado: (2013)

CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity
por: Krzywinska, Ewelina, et al.
Publicado: (2016)

SULFs in human neoplasia: implication as progression and prognosis factors
por: Bret, Caroline, et al.
Publicado: (2011)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study
por: Duroux-Richard, Isabelle, et al.
Publicado: (2022)

Adipose Mesenchymal Stem Cells Isolated after Manual or Water-jet-Assisted Liposuction Display Similar Properties
por: Bony, Claire, et al.
Publicado: (2016)

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
por: Kassambara, Alboukadel, et al.
Publicado: (2012)

Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis
por: Cren, Maïlys, et al.
Publicado: (2020)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

Lenalidomide Augments Differentiation of Cultured Hair Follicle Derived Melanocyte Stem Cells Into Functional Melanocytes
por: Kumari, Uma, et al.
Publicado: (2023)

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia
por: Lapierre, Marion, et al.
Publicado: (2015)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients
por: Bou Samra, Elias, et al.
Publicado: (2014)

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients
por: Bou Samra, Elias, et al.
Publicado: (2012)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

APRIL is overexpressed in cancer: link with tumor progression
por: Moreaux, Jérôme, et al.
Publicado: (2009)

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
por: Viziteu, Elena, et al.
Publicado: (2016)

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2013)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1jdbtq7leqsg2tfrtd4ai1aco8